Author: admin

  • Pakistan men, women enjoy ‘amazing day’ at LATAM Cup

    Pakistan men, women enjoy ‘amazing day’ at LATAM Cup

    CORAL SPRINGS, Fla. — Donny Khan had a timeline for the Pakistan men’s and women’s hockey teams he helped formed to become successful at the Amerigol LATAM Cup and other tournaments.

    “I thought we’d be winning several years from now,” said Khan, who is the NHL’s senior director of hockey development and strategic collaboration. “I didn’t think we’d be doing this in Year 2.”

    Pakistan’s men defeated Peru 6-1 to win the Division III championship of the LATAM Cup on Wednesday. They were undefeated (5 -0) in tournament play and the playoffs after winning only one game last year, when they participated in the LATAM Cup for the first time.

    The women’s team won the Division II bronze medal in its LATAM Cup debut.

    “You can’t do better than this first gold, first cup,” said Kameron Sabir, an Edmonton physician who coached the men’s team. “It’s just an amazing day for the country and ice hockey. The women did such an amazing job too. Tremendous (performance) for their first tournament. They had only 10-12 players, so hats off to them.”

    Mariya Rauf, who coached Pakistan’s women, clutched a cricket bat given to her by her players and smiled while watching the men celebrate their victory against Peru.

    “Cricket is our national sport,” said Rauf, a junior forward on Yale University’s NCAA Division I women’s hockey team. “But I think after this, it just shows hockey’s growing very single day. This shows that there’s talent and that we’re just going to keep getting better.”

    For Peru’s men, the sting of defeat was somewhat eased knowing they reached the championship game in their first LATAM Cup appearance.

    “First time Peru has an ice hockey team ever,” captain Christian Clement said. “Our goalie is from Lima, Peru; it was his first time playing in an ice tournament. He’s a roller hockey goalie. We play roller hockey in Peru. We’re pushing hard to play both games, roller and ice. This is how we grow the game in Peru.”

    This year’s LATAM Cup features 62 women’s, men’s and youth teams (with four more exhibition teams) and more than 1,450 players representing 17 countries and territories, including Argentina, Armenia, Brazil, Chile, Colombia, Costa Rica, Greece, Israel, Lebanon, Mexico, Peru and Puerto Rico. The tournament got underway Sunday and continues through Aug. 24.

    Continue Reading

  • First Coral Reef Discovered In Australia For 120 Years Was 500 Meters Tall, That’s Bigger Than The Empire State Building

    First Coral Reef Discovered In Australia For 120 Years Was 500 Meters Tall, That’s Bigger Than The Empire State Building

    It’s funny how nature can conceal giants for a surprising amount of time. We humans are constantly searching for things, so how is it that Australia didn’t find its heaviest insect (a stick insect that’s really more of a log insect) until just this year? You might also be surprised to learn that it wasn’t until 2020 that they discovered their first new reef in 120 years, one that just happened to be taller than the Empire State Building.

    The rest of this article is behind a paywall. Please sign in or subscribe to access the full content.

    Yes, this was the story that unfolded in the waters surrounding the Great Barrier Reef (GBR) in Australia. The reef is made up of almost 3,000 individual reefs and gained its first extra member in over a century back in 2020.

    It was happy news as the coral appeared to be in good health, despite most of the GBR having been devastated by a series of mass bleaching events. On top of that, it was also absolutely eye-wateringly enormous.

    The coral reef was discovered by a team with the Schmidt Ocean Institute who were conducting underwater mapping of the northern GBR seafloor. The team were then able to dive down and explore the reef with the help of their remote operated vehicle, SuBastian (who recently discovered Barbie lobsters and sea pigs in a previously unexplored offshore canyon).

    Mapping revealed the detached reef to be over 500 meters (1,640 feet) tall, making it taller than the Empire State Building, the Sydney Tower, and the Petronas Twin Towers. At its base, the reef is 1.5 kilometers (0.9 miles) long, but quite narrow. From there it rises 500 meters to support a small reef 300 meters (984 feet) long and only 15 meters (49 feet) wide lying just 40 meters (130 feet) below the surface. An ocean giant hiding just out of sight.

    “To find a new half-a-kilometer tall reef in the offshore Cape York area of the well-recognized Great Barrier Reef shows how mysterious the world is just beyond our coastline,” said Dr Jyotika Virmani, executive director of Schmidt Ocean Institute, in a release. “This powerful combination of mapping data and underwater imagery will be used to understand this new reef and its role within the incredible Great Barrier Reef World Heritage Area.” 

    Dr Robin Beaman of James Cook University told IFLScience the reef supports all the main ingredients of a thriving tropical reef, with “hard corals, soft corals, fish, and sharks.” So many sharks, in fact, that team member Mardi McNeil of Queensland University of Technology referred to a “blizzard of fish and sharks.” The staggering biodiversity is a contrast to the shallow water reefs nearby in the GBR’s northern zone, most of which have been hit hard by mass bleaching event.

    The reef was so full of “hard corals, soft corals, fish, and sharks,” team members described it as a “blizzard of fish and sharks”.

    The discovery of the new, skyscraper-sized reef brought the total number of detached reefs in the area to eight, reefs we’ve been mapping since the late 1800s. Other reefs like it include the Raine Island reef, which is the world’s most important green sea turtle nesting area.

    “This unexpected discovery affirms that we continue to find unknown structures and new species in our Ocean,” added Wendy Schmidt, co-founder of Schmidt Ocean Institute. “The state of our knowledge about what’s in the Ocean has long been so limited. Thanks to new technologies that work as our eyes, ears and hands in the deep ocean, we have the capacity to explore like never before. New oceanscapes are opening to us, revealing the ecosystems and diverse life forms that share the planet with us.”

    Continue Reading

  • Caterpillar and Hunt Energy Company, L.P. Sign Long-Term Strategic Agreement to Deliver Power Solutions for Data Centers – Caterpillar

    1. Caterpillar and Hunt Energy Company, L.P. Sign Long-Term Strategic Agreement to Deliver Power Solutions for Data Centers  Caterpillar
    2. World’s largest data center campus could be coming to central Utah  KSL.com
    3. Caterpillar And Hunt Energy Sign Long-Term Agreement To Deliver Power Solutions For Data Centers  Stocktwits
    4. ‘Golden Spike of the internet’: Why AI data centers are coming to Delta  ABC4 Utah
    5. Data center project has first tenant  Millard County Chronicle Progress

    Continue Reading

  • Nanodroplet array revolutionizes search for new drugs

    Nanodroplet array revolutionizes search for new drugs

    Until now, the early phase of drug discovery for the development of new therapeutics has been both cost- and time-intensive. Researchers at KIT (Karlsruhe Institute of Technology) have now developed a platform on which extremely miniaturized nanodroplets with a volume of only 200 nanoliters per droplet – comparable to a grain of sand – and containing only 300 cells per test can be arranged. This platform enables the researchers to synthesize, characterize, and test thousands of therapeutic agents on the same chip, saving time and resources. The researchers report on their findings in the journal “Angewandte Chemie” (DOI: 10.1002/anie.202507586)

     

    Drug discovery for new therapeutic agents currently relies on high-throughput screenings that comprise separate, resource-intensive steps for the synthesis, biological testing, and characterization of new active substances. This method is generally practicable only at major pharmaceutical companies, takes several years of development, incurs costs of hundreds of millions of euros, and requires a large amount of raw materials.

    In particular, academic and smaller industrial research institutions are not able to mobilize these resources. Our technology removes this barrier and could open the door for many more players to contribute to drug discovery.”


    Professor Pavel Levkin from KIT’s Institute of Biological and Chemical Systems (IBCS)

    1,000 times smaller droplets in experimental settings

    To accelerate drug discovery for cancer therapy, researchers from the Department of Biofunctional Materials headed by Levkin have now developed an integrated nanodroplet array platform. “It combines the previously separate processes for the development of new anti-cancer drugs on a single chip – using a single, miniaturized workflow,” says Levkin.

    The scientists managed to scale down the experiments by a factor of 1000, i.e., from the microliter to the nanoliter range. “Thanks to our direct-to-biology approach, where direct biological tests of the synthesized molecules are conducted without prior preparation, we are able to reduce the time and resources invested in synthesis and screening drastically by using only 200 nanoliters per droplet and 300 cells for each test – comparable in volume to a grain of sand,” says Levkin.

    The researchers synthesized and tested various potential MEK inhibitors (mitogen-activated protein kinase inhibitors) – agents that block the MEK enzyme, which is involved in the development of different types of cancer, such as skin and colon cancer. One well-known MEK inhibitor, mirdametinib, is already used for treating rare, inoperable tumors. Based on its molecular structure, the research group produced a library of potential novel MEK inhibitors. “Using the new nanodroplet method, we produced 325 potential MEK inhibitors in just seven days — and found that 46 of them worked as well as mirdametinib in lab tests,” says Levkin.

    Cell-based tests in miniature format

    The researchers examined the activity of the newly produced molecules using live cells. “In this process, we investigated the viability of the colon cancer cell line HT-29, which is vulnerable to MEK inhibitors,” says Liana Bauer, doctoral researcher at the IBCS-FMS and lead author of the published study.

    For characterization of the molecules, the team used the MALDI-MSI method (matrix-assisted laser desorption/ionization- mass spectrometry imaging). This technology allows the researchers to analyze the chemical composition of samples and visualize their spatial distribution. The analysis was conducted in cooperation with a research group led by Professor Carsten Hopf from the Center for Mass Spectrometry and Optical Spectroscopy (CeMOS) at TH Mannheim (Technical University of Applied Sciences).

    With the new array, it was possible to analyze all 325 products in triplicate, a total of 975 single samples, directly on the chip. “We were able to show that this method also works at an extremely small scale with nanodroplets,” explains Bauer.

    By combining molecule synthesis, testing, and analysis on a single platform, the new approach could make high-throughput drug discovery more accessible to academic labs and smaller biotech companies. “This is a big step toward faster, cheaper, and more efficient discovery of urgently needed new drugs,” says Levkin.

    Source:

    Karlsruhe Institute of Technology

    Journal reference:

    Seifermann, M., et al. (2025). Nanodroplet Array Platform for Integrated Synthesis and Screening of MEK Inhibitors: a Miniaturized Approach to Early Drug Discovery. Angewandte Chemie International Edition. doi.org/10.1002/anie.202507586.

    Continue Reading

  • NASA begins building Artemis III rocket at Kennedy Space Center – Aerospace Manufacturing

    1. NASA begins building Artemis III rocket at Kennedy Space Center  Aerospace Manufacturing
    2. NASA’s Final Piece of Artemis II Rocket Hardware Leaves Marshall  NASA (.gov)
    3. Huntsville adapts to role in next mission to moon  The Redstone Rocket
    4. NASA putting final pieces together for Artemis II mission  MSN
    5. NASA starts bolting together Artemis III rocket for 2027 Moon shot  theregister.com

    Continue Reading

  • China’s Commercial Space Industry Is Facing Bottlenecks, Insiders Say

    China’s Commercial Space Industry Is Facing Bottlenecks, Insiders Say

    (Yicai) Aug. 21 — Despite a recent flurry of launches, progress in China’s commercial space sector is being held back by bottlenecks in capacity and technology, industry insiders have told Yicai.

    There have been nine rocket launches in China in the past 25 days, more than a quarter of the total in the first half of the year. But there have also been problems that pointed to ongoing issues in the sector.

    Last week, startup Landspace experienced a failure following an anomaly during the launch of its Zhuque-2E Y3 carrier rocket. The specific reason for the failure has not yet been made public.

    Launch costs are a growing concern. Satellites prices have come down, thanks to manufacturing maturity in China, but the cost of putting them into orbit can be more than the satellite itself, a senior executive at a satellite manufacturer told Yicai.

    A single launch costs around CNY150,000 (USD20,900) per kilogram, the person said, meaning that putting a 500-kilogram satellite into space can cost as much as CNY75 million (USD10.4 million).

    “It’s pricey, very pricey,” said Jiang Luye, chief technology officer at Xingsuo Technology, a maker of reusable liquid-fuelled rockets. If carrying capacity can be improved, more satellites can be put into orbit in just one launch, Jiang said, noting that this capacity depends on the performance of the engines and their potential for recycling.

    But there are technical problems in the most common rocket technology used in China, which uses kerelox, a mixture of kerosene and liquid oxygen. It creates deposits that are hard to clean, Jiang said, which adds to the costs. By comparison, the famed Raptor engine in US-based SpaceX’s rockets uses liquid oxygen and methane, which is more suitable for reuse.

    Jiang said his company is researching a new generation of rockets that will have much greater liftoff weight. “The greater the single-time carrying capacity is, the lower the general launching costs will be,” he said, adding that costs could be cut by 50 percent or more.

    The company is now 60-strong, with staff drawn from various prestigious Chinese universities and it will expand to around 200 people by the end of this year, Jiang said. Research efforts will focus on rocket recycling and engine technology, he noted.

    Editor: Tom Litting

    Continue Reading

  • Models Based on Serum Proteomics Improve Risk Prediction in ADPKD – Docwire News

    Models Based on Serum Proteomics Improve Risk Prediction in ADPKD – Docwire News

    1. Models Based on Serum Proteomics Improve Risk Prediction in ADPKD  Docwire News
    2. Scientists discover new ways to predict course of chronic kidney disease  The University of Manchester
    3. New Biomarker Models Offer Mechanistic Insights in Chronic Kidney Disease Management  Managed Healthcare Executive
    4. These biomarkers may predict organ failure, death in chronic kidney disease  Business Standard
    5. Simple blood, urine tests may help predict chronic kidney disease progression  Daijiworld

    Continue Reading

  • Peer reviewers more likely to approve articles that cite their own work

    Peer reviewers more likely to approve articles that cite their own work

    Reviewers are more likely to approve a manuscript if their own work is cited in subsequent versions than reviewers who are not cited, according to an analysis of 18,400 articles from four open access publications. The study, which is yet to be peer reviewed, was posted online as a preprint earlier this month.

    The study was inspired by anecdotes from authors who cited articles only because reviewers asked them to, says study author Adrian Barnett, who researches peer review and metaresearch at Queensland University of Technology in Brisbane, Australia. Sometimes, these requests are fine, he says. But if reviewers ask for too many citations or the reason to cite their work is not justified, the peer-review process can become transactional, says Barnett. Citations increase a researcher’s h-index, a metric reflecting the impact of their publications.

    Requesting unnecessary or unjustified requests for citations, sometimes called coercive citation, is generally considered poor practice. Balazs Aczel, a psychologist who studies metascience at Eötvös Loránd University in Budapest, says that the latest work isn’t the first to investigate reviewers asking for citations, but that the number of peer reviews included and level of analysis is novel. A barrier to studying the practice is a lack of data sharing from publishers, he says.

    Approve, reject, reservations

    The preprint considered articles from four publishing platforms — F1000Research, Wellcome Open Research, Gates Open Research and Open Research Europe — that make all versions of their articles publicly available, as well as reviewer comments. The publishers ask reviewers to approve articles, reject or approve them with reservations. Reviewers are also asked to explain why they ask authors to cite their own work. Of 37,000 reviews — at least two people reviewed each article — 54% of reviewers approved articles with no changes and rejected 8%. Almost 5,000 reviewed articles cited a reviewer and roughly 2,300 reviews requested a citation from a reviewer.

    The analysis found that reviewers who were cited were more likely to approve the article after the first review than reviewers who were not cited.

    But reviewers who suggested that their own research be cited were about half as likely to approve the article than reject it or express reservations. In more than 400 reviews in which the reviewer was not cited in version 1 of the article and requested a citation in their review, 92% of reviewers who were cited in version 2 recommended approval compared with 76% for reviewers who were not cited.

    When a reviewer rejects a paper, they and the authors know that the reviewer is probably going to evaluate any revised versions of the article, says Barnett, so authors might opt for the path of least resistance and include the citation to get their paper accepted.

    Reviewer comments

    Barnett also analysed 2,700 reviewer comments and identified the 100 most frequently used words. He found that reviewers who requested citation were more likely to use words such as ‘need’ or ‘please’ in their comments when they rejected an article, which he says suggests that coercive language was used.

    Jan Feld, a metascience researcher at the Victoria University of Wellington, New Zealand, is not convinced that such language is a sign of coercion. “That seems like a bit of a stretch,” he says. There are other explanations for reviewers rejecting an article than the author refusing to cite their work. He doesn’t doubt that reviewers request citations that are not warranted, but they can recommend citations, including of their own work, to address issues they’ve identified. But even after those recommendations, “if the paper has not improved or I still have concerns, I cannot recommend publication”, he adds.

    Continue Reading

  • Australian researchers identify GATOR1 complex as key to preventing lymphoma

    Australian researchers identify GATOR1 complex as key to preventing lymphoma

    Australian researchers have used an innovative genome-wide screening approach to identify genes, and their encoded proteins, that play critical roles in the prevention of lymphoma development, revealing new potential treatment targets for these blood cancers. 

    The study, published in Nature Communications today, has identified a group of proteins known as the GATOR1 complex as essential tumor suppressors. 

    The GATOR1 complex normally functions as a ‘brake’ on cellular growth by regulating pathways that control cell growth and metabolism. When GATOR1 components are lost or defective, this protective mechanism fails, allowing cells to grow uncontrollably. 

    The research is a collaboration between the Olivia Newton-John Cancer Research Institute (ONJCRI), WEHI, and the Peter MacCallum Cancer Centre. 

    The team utilized sophisticated pre-clinical models of aggressive lymphoma to systematically test the function of all known genes in this complex. Their comprehensive screening approach revealed that when any of the GATOR1 genes are lacking, lymphoma development is dramatically accelerated, identifying the GATOR1 complex as a crucial suppressor of blood cancer development. 

    Co-lead author Dr Margaret Potts said: “The best thing about performing a well-designed CRISPR screen is that you will always find something. 

    “Our unbiased screening approach looked at all genes, rather than just a subset of them. By not limiting our investigation to known pathways, we found expected as well as unexpected tumor suppressor genes and pathways, such as GATOR1.” 

    Strikingly, existing drugs that target the same cellular pathways that GATOR1 typically controls were highly effective at slowing the growth of lymphomas in GATOR1-deficient pre-clinical models. 

    These drugs have previously had limited success in cancer treatment, and this may be because researchers have not been able to identify which patients would respond well to these therapeutics. 

    “Our paper begins the exploration into this precision medicine opportunity,” shared Dr Potts. 

    Prof Marco Herold, CEO of ONJCRI, Head of the La Trobe School of Cancer Medicine and senior author of the Nature Communications paper, said: 

    “Our pre-clinical lymphoma model is driven by high levels of the oncogene MYC, an abnormality that can be found in ~70% of all human cancers. When GATOR1 is lacking, it removes a critical brake that normally slows MYC-driven malignancy. 

    This exciting discovery provides a new insight into the development and sustained expansion of cancer, which we hope will underpin the development of more effective, targeted treatments for cancer.” 

    According to the Global Cancer Observatory, there were over 630,000 new cases of lymphoma worldwide in 2022, highlighting the urgent need for better understanding of the molecular mechanisms that drive this disease.

    The research was led by Dr Margaret Potts, Dr Shinsuke Mizutani, and Dr Yexuan Deng, under the supervision of Prof Marco Herold, Prof Andreas Strasser (WEHI), and A/Prof Kristin Brown (Peter Mac). 

    Source:

    Journal reference:

    Potts, M. A., et al. (2025). Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphoma. Nature Communications. doi.org/10.1038/s41467-025-62615-y.

    Continue Reading

  • A&O Shearman posts USD3.7bn revenue, marking strong first year

    A&O Shearman posts USD3.7bn revenue, marking strong first year

    Landmark client successes 

    •  Liberty Global on its USD3.2bn Sunrise Communications spin-off and dual listing
    • Prosus on its EUR4.1bn acquisition of Just Eat Takeaway.com
    • Exscientia on its combination with US-based biotech company Recursion
    • The lenders on the restructuring of over USD11.5bn in offshore debt for Shimao Group Holdings
    • The underwriters on TD Bank’s USD14.6bn exit from Charles Schwab
    • The underwriters and funders on the EUR5.8bn debt refinancing of XpFibre
    • Uber on a litigation victory in a Securities Exchange Act case against Uber and its officers
    • SAP on a litigation victory in connection with the USD12.5bn sale of Qualtrics to Silver Lake Capital 

    Innovation leadership – pioneering AI and transforming legal delivery through technology 

    The firm continues to advance the boundaries of technology for lawyers. A&O Shearman was the first firm globally to deploy generative AI enterprise-wide when it rolled out Harvey in 2022. ContractMatrix, the firm’s award-winning AI-based contract management platform, is built in collaboration with Harvey and Microsoft. 

    In April 2025, the firm began rolling out a suite of agentic AI agents, built in partnership with Harvey, that tackle complex legal workflows. The initial agents focus on antitrust filing analysis, cybersecurity, fund formation, and loan review – high-value areas requiring deep legal expertise and multi-step reasoning. 

    A&O Shearman brings this understanding of AI technologies (and the infrastructure used to build them) and real-world AI governance to deliver innovative and uniquely pragmatic advice to clients on managing AI legal risk. The firm has dedicated AI experts in every major jurisdiction across the full risk spectrum and every stage of the AI value chain. The firm counsels numerous tech and industry giants, some of the largest AI foundation model developers, three of the five biggest Western banks in the world, and a G20 country on its national AI strategy and AI regulation.

    A&O Shearman has begun FY26 with landmark client wins, including advising Partners Group on its joint acquisition of Techem – the largest M&A transaction in Germany this year; Athora on its GBP5.7bn acquisition of Pension Insurance Corporation Group; Sanmina in its USD3bn acquisition of ZT Systems’ data center business; the lenders on EQT’s USD5.5bn acquisition of Fortnox AB; Froneri on its EUR4.25bn financing; and Sizewell C on its supply chain and contracting strategy for the GBP38bn nuclear project.

    Continue Reading